Study of Biogen

Posted on July 11, 2020 by Timeless Investor

Study of Biogen

07/10/2020 – Good news for Biogen

Biogen Stock Is Jumping. The Biotech Submitted Its Troubled Alzheimer’s Drug for FDA Approval.

FDA approval of Biogen’s Aducanumab could change the Alzheimer’s treatment landscape

About Timeless Investor

My name is Samual Lau. I am a long-term value investor and a zealous disciple of Ben Graham. And I am a MBA graduated in May 2010 from Carnegie Mellon University. My concentrations are Finance, Strategy and Marketing.
This entry was posted in Equity Analysis and tagged . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *